GS 9350

Known as: 9350, GS, GS-9350, GS9350 
 

Topic mentions per year

Topic mentions per year

2009-2014
01220092014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
PURPOSE This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy… (More)
Is this relevant?
2014
2014
The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
Is this relevant?
2012
2012
There are 26 approved antiretroviral drugs available in 2012 in 6 mechanistic classes: reverse transcripatase inhibitors (both… (More)
Is this relevant?
2011
2011
OBJECTIVE To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection. DESIGN… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2011
Review
2011
Elvitegravir is a potent, boosted, once-daily, HIV integrase inhibitor with antiviral activity against wild-type and drug… (More)
Is this relevant?
2010
2010
GS-9350 is a new chemical entity under development as a potent, mechanism-based inhibitor of human cytochrome P450 3A (CYP3A… (More)
Is this relevant?
2010
2010
Cobicistat (3, GS-9350) is a newly discovered, potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. In… (More)
Is this relevant?
2010
2010
OBJECTIVE This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2009
2009
  • AIDS patient care and STDs
  • 2009
 
Is this relevant?